Food and Drug Administration
January 6, 2003
Slides
Cozaar® (losartan potassium) Tablets
Disclaimer
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
COZAAR (losartan) in Hypertensive Patients with Left Ventricular Hypertrophy, Dr. Jeffrey Tucker, MD, Merck Research Lab. (HTM) (PPT)
Backup Information, Merck Research Lab. (PDF)
Backup Information, Merck Research Lab. (PDF)
Analysis of LIFE Study by Ethnic Demographic Subgroup, John Lawrence, FDA (HTM) (PPT)